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Abstract
Background: Current therapies for advanced renal cell carcinoma (RCC) have low cure rates or significant side
effects. It has been reported that complexes composed of interleukin (IL)-2 and stimulating anti-IL-2 antibody (IL-2C)
suppress malignant melanoma growth. We investigated whether it could have similar effects on RCC.
Methods: A syngeneic RCC model was established by subcutaneously injecting RENCA cells into BALB/c mice,
which were administered IL-2C or phosphate-buffered saline every other day for 4 weeks. RCC size was measured
serially, and its weight was assessed 4 weeks after RENCA injection. Immune cell infiltration into RCC lesions and
spleen was assessed by flow cytometry and immunohistochemistry.
Results: IL-2C treatment increased the numbers of CD8+ memory T and natural killer (NK) cells in healthy BALB/c mice
(P < 0.01). In the spleen of RCC mice, IL-2C treatment also increased the number of CD8+ memory T, NK cells, and
macrophages as compared to PBS-treated controls (P < 0.01). The number of interferon-γ- and IL-10-producing
splenocytes increased and decreased, respectively after 4 weeks in the IL-2C-treated mice (P < 0.01). Tumor-infiltrating
immune cells including CD4+ T, CD8+ T, NK cells as well as macrophages were increased in IL-2C-treated mice than
controls (P < 0.05). Pulmonary edema, the most serious side effect of IL-2 therapy, was not exacerbated by IL-2C
treatment. However, IL-2C had insignificant inhibitory effect on RCC growth (P = 0.1756).
Conclusions: IL-2C enhanced immune response without significant side effects; however, this activity was not
sufficient to inhibit RCC growth in a syngeneic, murine model.
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Background
Renal cell carcinoma (RCC) is the most common
primary malignancy of the renal parenchyma, compris-
ing 3 % of all adult malignancies, and its incidence has
been increasing [1, 2]. Although early RCC can be
cured by surgery, one-third of RCC patients exhibit
metastasis at diagnosis. Metastatic RCC has poor prog-
nosis, with a 5-year survival rate of only 10 % [3], and
approximately 20-25 % of patients with metastatic RCC
do not respond to treatment and symptoms progress
rapidly [4]. Sorafenib is one of target drugs against
RCC that prolongs patient survival, but rarely leads to
complete remission [5–7]; moreover, long-term sorafe-
nib treatment can exacerbate RCC by creating ischemic
conditions [8, 9].
RCC is considered as an immunogenic tumor owing
to its spontaneous regression, variable growth, late
metastasis, high degree of T cell infiltration, and high
incidence in immunosuppressed patients. However,
RCC can also suppress the anti-tumor immunity of
naïve and memory CD4+ T, natural killer (NK), and
dendritic cells [10], and evade the cytotoxic effect of
NK cells [11, 12]. Therefore, a drug that potentiates
immune response may be effective in the treatment of
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RCC. Indeed, high doses of interleukin (IL)-2 have
been shown to suppress RCC progression without in-
ducing tumor ischemia, leading to complete remission
in 10–20 % of patients [13, 14]. Blockade of CTLA4, a
T-cell inhibitory receptor with ipilimumab, and in-
creasing T-cell proliferation and cytotoxic effects with
PD-1/PD-L1 axis inhibition also induced regression of
renal cell carcinoma in some patients [15, 16]. How-
ever, high-dose IL-2 therapy also induces systemic
inflammatory responses, including capillary leak syn-
drome, heart failure, and pulmonary edema, thereby
hindering the broad application of high-dose IL-2
therapy in the treatment of advanced RCC [17, 18].
Recently, immune complexes (IL-2C) composed of
with low-dose IL-2 and stimulating anti-IL-2 antibody
(S4B6) have been shown to enhance immune responses
via selective structural interactions [19–23]. Stimulating
IL-2C can preferentially expand memory CD8+ T and
NK cells—while more weakly affecting regulatory T
cells—via the interaction of anti-IL-2 antibodies (S4B6)
and CD25 binding region of IL-2, leading to inhibition
of both leukemia and melanoma [19, 23]. Interestingly,
the half-life of IL-2 is increased in IL-2C; as such, low-
dose IL-2C has immune enhancing effects that are com-
parable to those of high-dose IL-2 therapy without
accompanying serious side effects such as capillary leak
syndrome [19, 23]. Low-dose IL-2C therapy is therefore
expected to be an effective and safe treatment for im-
munogenic tumors.
Here, we investigated the efficacy and safety of low-dose
IL-2C treatment for RCC in a syngeneic murine model. We
found that IL-2C treatment enhanced anti-tumor immunity
against RCC without causing pulmonary edema, although




The RENCA, a murine RCC cell line from a BALB/c
mouse background was purchased from Korean Cell line
Bank (Seoul, Korea), and cultured in Eagle’s Minimum
Essential Medium (Gibco/Invitrogen, Grand Island, NY,
USA) containing 10 % fetal bovine serum (Gibco/Invitro-
gen) at 37 °C and 5 % CO2. BALB/c mice were purchased
from Orient Bio Inc. (Seongnam, Korea) and maintained
at the Biomedical Research Institute of Seoul National
University Hospital. Mouse experimental protocols were
approved by the Animal Ethics Committee of Seoul
National University College of Medicine.
Fig. 1 IL-2C treatment induces the expansion of CD8+ memory T and NK cells in the spleen. Mice were treated with IL-2C by intraperitoneal injection for
5 days. The total numbers of (a) splenocytes, (b) CD8+ T cells, (c) CD8+ memory T cells, (d) and NK cells were higher in IL-2C-treated than in PBS-treated
mice (P< 0.010)
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Preparation of IL-2/anti-IL-2 antibody complex
Recombinant murine IL-2 was purchased from eBioscience
(San Diego, CA, USA) and the S4B6 anti-mouse IL-2
monoclonal antibodies was provided by Dr. Charles D.
Surh (La Jolla Institute for Allergy and Immunology, La
Jolla, CA, USA). S4B6 (7.5 μg) was mixed with IL-2 (1.5 μg,
equivalent to 8555 IU) and incubated at 37 °C for 30 min
before use. To evaluate the immune-enhancing effects of
Fig. 2 IL-2C treatment induces the expansion of immune cells in the spleen of mice with RCC. Syngeneic RENCA cells were implanted
subcutaneously in mice, and IL-2C or PBS was administered every other day for 4 weeks. (a) The number of CD4+ T cells was similar between the
two groups (P = 0.498), while the numbers of (b) CD8+ T cells, (c) CD8+ memory T cells, (d) NK cells, (e) macrophages, and (f) Tregs were higher
in the IL-2C group than in the PBS group (P < 0.010). (g, h) CD8+ memory T cell/Treg and NK cell/Treg ratios were higher in the IL-2C group than
the PBS group (P < 0.010 in both cases). Treg, regulatory T cell
Han et al. BMC Urology  (2016) 16:2 Page 3 of 11
IL-2 under normal conditions, IL-2C or phosphate-
buffered saline (PBS) was administered daily to mice by
intraperitoneal injection for 5 days, before the spleen was
harvested for immune cell analysis.
In vivo tumor model
Eight-week old BALB/c mice were subcutaneously
injected with RENCA cells (1 × 105) in 0.1 ml of 1× PBS
to induce syngeneic RCC formation. IL-2C (treatment
group) or PBS (control group) was intraperitoneally
administered to mice every other day from day 0 to 28.
Tumor size (length × width) was measured every other
day using calipers. IL-2C with S4B6 (7.5 μg) and IL-2
(1.5 μg) or phosphate-buffered saline (PBS) was adminis-
tered every 2 days to mice by intraperitoneal injection
until 28 days. In high-dose IL-2 group, higher dose of
IL-2 (35 μg, 200,000 IU) was administered to mice with
the same schedule. Spleen, lung and tumor tissues were
harvested 28 days after injection of RENCA cells. Tumor
weight was measured after harvest. Pulmonary edema
was assessed by lung weight, which was calculated by
subtracting the dry weight from the wet weight.
Flow cytometry
Splenocytes were labeled with the following antibodies:
anti-CD4-allophycocyanin (APC), anti-CD8-fluorescein
isothiocyanate (FITC), anti-CD44-APC, anti-CD45-FITC,
anti-CD49-phycoerythrin (PE), and anti-F4/80-PE and the
vital dye 7-aminoactinomycin D (7-AAD) (BD Biosci-
ences, San Jose, CA, USA). Forkhead homeobox protein 3
(Foxp3) was labeled using the anti-mouse Foxp3-FITC
staining kit (eBioscience) according to the manufacturer’s
instructions. For analysis of tumor-infiltrating cells,
tumors were dissociated with 200U/ml collagenase IV at
37 °C for 30 min. Flow cytometric analysis was carried out
on a Canto II Instrument (BD Biosciences).
Enzyme-linked immunoSPOT (ELISPOT) assay
Interferon (IFN)-γ- or IL-10-producing T cells were
detected with the ELISPOT assay. Spleens were har-
vested 28 days after mice were injected with RENCA
cells. A 96-well plate was coated with anti-IFN-γ or -IL-
10 capture antibodies using ELISPOT mouse IFN-γ or
mouse IL-10 kits (BD biosciences). For IFN-γ ELISPOT,
splenocytes (1 × 105/well) were incubated with 5 ng/ml
phorbol 12-myristate 13-acetate (Sigma, St. Louis, MO,
USA) and 500 ng/ml of inomycin (Sigma) at 37 °C for
8 h. For IL-10 ELISPOT, splenocytes (5 x 105/well) were
incubated with 1 μg/ml of lipopolysaccharide (Sigma) for
24 h. Detection antibodies were then added, along with
horseradish peroxidase (HRP)-streptavidin (BD Biosci-
ences). After adding 3'-amino-9-ethylcarbazole substrate
(BD Biosciences) for development, colored spots were
measured with an ELSPOT reader (Cellular- Technology,
Cleveland, OH, USA).
Immunohistochemistry
Tumor tissue with overlying skin was harvested on day
28. Anti-CD4, anti-CD8, anti-CD49b and anti-F4/80
antibodies (eBioscience) were incubated with tissue
sections at 4 °C overnight. Sections were then treated
sequentially with secondary antibody (ZytoChem Plus
HRP One-Step Polymer anti-mouse; Zytomed, Berlin,
Germany) and substrate solution (ImmPACT NovaRED
Peroxidase Substrate Kit; Vector, Burlingame, CA, USA).
Pulmonary edema was assessed by hematoxylin and
eosin staining.
Statistical analysis
Continuous variables were compared between the IL-2C
and the PBS groups using the Student’s t-test. RCC growth
over 4 weeks was compared between the two groups with
the linear mixed model. A P value < 0.050 was considered
statistically significant. Analyses were carried out using
SPSS v.22.0 software (SPSS Inc., Chicago, IL, USA).
Fig. 3 IL-2C treatment increases the number of IFN-γ+ splenocytes, but decreased the number of IL-10+ splenocytes. After syngeneic RENCA cells
were implanted in mice, splenocytes were harvested on day 28 and analyzed for IFN-γ and IL-10 production by ELISPOT. a, b The number of IFN-
γ-producing splenocytes was higher (a) but the number of IL-10-producing splenocytes were lower (b) in IL-2C-treated mice than in PBS-treated
mice (P < 0.010 in both cases)
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Results
IL-2/anti-IL-2 antibody complex treatment induces the
expansion of CD8+ memory T and NK cells in the spleen
IL-2C were injected into healthy mice for 5 consecutive
days to evaluate its immune-enhancing effects. The total
numbers of splenocytes (Fig. 1a; P < 0.010) and CD8+ T
cells (Fig. 1b; P < 0.010) were increased in the IL-2C
group as compared to the PBS group. IL-2C treatment
also increased the numbers of CD44+CD8+ memory T
(Fig. 1c; P < 0.010) and CD49b+ NK (Fig. 1d; P < 0.010)
cells. These results suggest that IL-2C treatment can
enhance anti-tumor immunity.
IL-2/anti-IL-2 antibody complex treatment induces the
expansion of CD8+ memory T and NK cells in the spleen
of RCC mice
Mice were subcutaneously injected with syngeneic
RENCA cells, followed by IL-2C or PBS administration
every other day for 4 weeks. A sham group received PBS
without RENCA cell implantation. Among RCC mice,
there was no difference in the number of CD4+ T cells
between the IL-2C and PBS groups (Fig. 2a; P = 0.498).
However, IL-2C treatment induced the expansion of CD8+
T, CD8+ memory T, and NK cells as well as macrophages
(Fig. 2b–e; P < 0.010), and increased the number of splenic
Fig. 4 Flow cytometric analysis of immune cell infiltration into RCC lesions. Tumors were harvested on day 28 after mice were implanted with
RENCA cells and immune cells were detected by flow cytometry. IL-2C treatment increased infiltration of (a) CD45+ cells (P < 0.010), (b) CD4+ T
cells (P < 0.010), (c) CD8+ T cells (P = 0.037), (d) NK cells (P = 0.033) (e) and macrophages (P < 0.010) into tumors
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CD4+Foxp3+ regulatory T cells (Fig. 2f; P = 0.040), albeit
to a lesser degree than for CD8+ memory T or NK cells.
As a result, CD8+ memory T cell/regulatory T cell (Fig. 2g;
P < 0.010) and NK cell/regulatory T cell (Fig. 2h; P < 0.010)
ratios were increased in the IL-2C relative to the PBS
group. These data indicate that IL-2C treatment enhances
anti-tumor immunity against RCC.
IL-2/anti-IL-2 antibody complex treatment increases IFN-
γ+ and decreases IL-10+ splenocyte populations
We analyzed Th1 and Th2 cytokine responses in the spleen
of RCC mice (Fig. 3). The number of IFN-γ-producing sple-
nocytes was lower in RCC mice treated with PBS than in
the sham group. Meanwhile, IL-2C-treated mice had a
higher number of IFN-γ+ splenocytes than those in the PBS
group (Fig. 3a; P < 0.010). The number of IL-10-producing
splenocytes was higher in RCC mice treated with PBS than
in the sham group (P < 0.010), but this was decreased by
IL-2C treatment (Fig. 3b; P < 0.01). These results indicate
that IL-2C can shift the immune response from Th2 to
Th1 in the RCC environment.
IL-2/anti-IL-2 antibody complex treatment increases
immune cell infiltration into RCC lesions
Given the immune-stimulating effects of IL-2C on the
spleen in RCC, we investigated whether immune cell in-
filtration of immune cells into RCC lesions was induced
by IL-2C treatment. Flow cytometric analysis showed
higher numbers of infiltrating CD45+ (Fig. 4a; P < 0.010),
CD4+ T (Fig. 4b; P < 0.010), CD8+ T (Fig. 4c; P = 0.037),
and NK (Fig. 4d; P = 0.033) cells as well as macrophages
(Fig. 4e; P < 0.010) in the IL-2C group than in the PBS
Fig. 5 Immunohistochemical analysis of immune cell infiltration into RCC lesions. Tumors were harvested on day 28 after mice were implanted
with RENCA cells and immune cells were detected by immunohistochemistry. The size of immune cell populations, including (a) CD4+ T cells, (b)
CD8+ T cells, (c) NK cells and (d) macrophages along tumor margins was increased by IL-2C treatment. Images are shown at 200× magnification.
Insets show immunoreactive cells at 1000× magnification
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group. In addition, an immunohistochemical analysis
found that IL-2C treatment increased CD4+ T, CD8+ T,
and NK cells as well as macrophages recruitment to
RCC lesions (Fig. 5). However, there was no perigraft in-
filtration of regulatory T cells (data not shown). Taken
together, these data demonstrate that IL-2C stimulates
the infiltration of immune cells into RCC lesions.
Anti-tumorigenic effects of IL-2/anti-IL-2 antibody complex
were not sufficient to suppress RCC growth
The size of RCC lesions increased progressively over time
in both PBS-treated and IL-2C-treated mice (Fig. 6a; P <
0.010); however, the rate of growth was higher in the
former group (Fig. 6a; P = 0.036), although the difference
was slight. However, tumor weights on day 28 did not differ
significantly between the two groups (Fig. 6b; P = 0.176).
These data suggest that the potentiation of anti-tumor im-
munity by IL-2C was not sufficient to suppress RCC
growth significantly.
IL-2/anti-IL-2 antibody complex treatment does not
induce pulmonary edema
Pulmonary edema is a manifestation of capillary leak
syndrome and is the most serious side effect of high-dose
of IL-2 therapy [23]. On day 28, there was no significant
difference in lung weights between IL-2C- and PBS-treated
mice (Fig. 7a; P = 0.184). A histologic examination revealed
no evidence of increased pulmonary edema by IL-2C treat-
ment (Fig. 7b). These results demonstrate that IL-2C is safe
for use, as it does not carry a significant risk of pulmonary
edema development.
Comparison between IL-2/anti-IL-2 antibody complex
treatment and high-dose IL-2 therapy
When immune potentiating effects of IL-2C were com-
pared with those of high-dose IL-2 therapy, the IL-2C
therapy increased total leukocytes, CD8+ T cells, NK cells,
and macrophages in both spleen (Fig. 8) and peritumor
tissues (data not shown) to greater extent than the high-
dose IL-2 therapy. The ratio of either splenic CD8+CD44+
T cells/Tregs or CD49b +NK cell/Tregs were not signifi-
cantly increased in the high-dose IL-2 group (Fig. 8d-e).
There was no difference in RCC weight between the IL-
2C group and the high-dose IL-2 group (Fig. 8f). Pulmon-
ary edema looked more severe in the high-dose IL-2 group
than IL-2 complex group (Fig. 8g); however there was no
significant difference in lung weight between the two
groups (P > 0.05). Taken together, IL-2C induced more im-
mune potentiating effects with lesser dose than high-dose
IL-2 therapy; however IL-2C did not show significant ben-
efits in either tumor reduction or pulmonary edema in the
present dose.
Discussion
The present study investigated for the first time the anti-
tumorigenic effects of IL-2C against RCC in vivo. We
found that stimulating IL-2C induced the expansion of
CD8+ memory T and NK cell populations, shifted the
Th1/Th2 balance in favor of Th1, and increased immune
cell infiltration into tumor tissue in mice with RCC, all
without inducing serious side effects such as pulmonary
edema. However, the enhancement of anti-tumor im-
munity by IL-2C was not sufficient to inhibit RCC
growth significantly.
IL-2C can enhance or suppress immunity depending
on the type of anti-IL-2 monoclonal antibody. For
example, the monoclonal antibody JES6-1 binds to the
IL-2 epitope, and hinders binding to IL-2 receptor (R)-β
while enabling binding to IL-2R-α. Since both CD8+
memory T and NK cells constitutively express IL-2R-β,
and regulatory T cells constitutively express both IL-2R-
β and IL-2R-α, an IL-2C comprising JES6-1 preferen-
tially induced the expansion of regulatory T cells [24]. In
contrast, S4B6 binds to an epitope of IL-2 such that
binding to IL-2R-α is blocked in favor of IL-2R-β
Fig. 6 IL-2C does not suppress growth of RCC significantly. a IL-2C
slowed the growth of syngeneic RENCA cells implanted subcutaneously
into mice (P = 0.036, linear mixed model). b Tumor weight on day 28 did
not differ significantly between the IL-2C and the PBS groups (P = 0.176,
Student’s t-test)
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binding [23]. Therefore, IL-2C comprising S4B6 induces
the expansion of CD8+ memory T and NK cells over
regulatory T cells.
Immune complexes consisting of low-dose IL-2 and
the S4B6 clone of the anti-IL-2 antibody was found to
inhibit metastasis of melanoma and leukemia in a mouse
model by inducing the expansion of CD8+ T and NK cell
populations [19, 23]. In accordance with these findings,
we also found that S4B6-containing IL-2C increased
CD8+ T and NK cell number as well as their infiltration
into RCC lesion, although the growth of RCC was not
significantly affected in a syngeneic RCC mice model.
There are a few possible explanations for the insuffi-
cient effects of IL-2C on RCC growth. Firstly, immuno-
suppression by RCC is strong enough to counter
immune-potentiating effects of IL-2C, which promotes
RCC proliferation and survival [10–12]. For instance,
RCC exhibits resistance to NK cell-mediated lysis, des-
pite IL-2C-induced NK cell expansion and infiltration
into RCC lesions [11, 12]. Secondly, the immunogenicity
of RCC may be lower than that of malignant melanoma.
Tumor-associated antigens are required for immune cell
infiltration into tumors [25, 26]; however, there are fewer
RCC-associated antigens than tumor-associated antigens
that have been found in melanoma [27]. Therefore, a
relative lack of targeting antigens may be a reason why
adoptive therapy with CD8+ tumor-infiltrating lympho-
cytes has not been clinically effective for RCC treatment
[28]. Third, lack of kidney-specific microenvironment
might have influenced the results. However, when we
injected RENCA cells into the renal subcapsular space,
the results were the same as those in the subcutaneous
RCC model (data not shown).
The amount of IL-2 that was used in IL-2C therapy
was 23 times lower than the amount of IL-2 in high-
dose IL-2 therapy [23]. Based on a previous report [23]
and our results, low-doses of IL-2C do not cause signifi-
cant adverse reactions such as pulmonary edema, and is
therefore safe for clinical application. However, because
even high-dose IL-2 therapy in the present study did not
increase lung weight significantly, further studies using
higher dose of IL-2C and IL-2 are needed to confirm
safety as well as insufficient efficacy of IL-2C in com-
parison to high-dose IL-2.
Since IL-2C alone cannot suppress RCC growth, add-
itional studies are needed to determine the impacts of
other therapies used in combination with IL-2C on
RCC. For example, IL-15 can also induce the expansion
Fig. 7 IL-2C does not exacerbate pulmonary edema in mice with RCC. Lung weight was measured by subtracting dry from wet weight
immediately after harvesting on day 28. a Lung weight did not differ significantly between IL-2C-treated mice and PBS-treated mice (P = 0.184). b
IL-2C treatment did not increase pulmonary edema, as visualized by hematoxylin and eosin staining. Images are shown at 400× magnification
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Fig. 8 Comparison between IL-2C therapy and high-dose IL-2 therapy. IL-2C treatment induces more expansion of splenic immune cells than
high-dose IL-2 therapy (a-e). a Both IL-2C (P = 0.004) and high-dose IL-2 (P = 0.008) increased the number of splenocytes; however, the effect of
IL-2C was greater than that of high-dose IL-2 (P = 0.019). b CD8+ T cells were also increased more by IL-2C than high-dose IL-2 (P = 0.006). c Only
IL-2C increased the number of NK cells (P = 0.002). d-e IL-2C increased both ratio of CD8+CD44+ T cells/Tregs (P = 0.002, d), and ratio of CD49b+
NK cells/Tregs (P = 0.001, e), whereas high-dose IL-2 did not. f Either IL-2C or high-dose IL-2 did not suppress growth of RCC significantly. Tumor
weight on day 28 did not differ significantly between the IL-2C and the high-dose IL-2 groups (P = 0.353). g Pulmonary edema looked
more severe in the high-dose IL-2 group than IL-2 complex group; however difference was not significant. Images are shown at 200×
magnification. IL-2C, interleukin-2/anti-interleukin-2 antibody complex; HD, high dose; Treg, regulatory T cell
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of NK and CD8+ T cell populations and thereby suppress
the growth of malignant melanoma [29], and a complex
of IL-15 and soluble IL-15Rα has even more potent ef-
fects [30]. Therefore, it is worth investigating whether
IL-2C used in conjunction with an IL-15 complex has
greater effectiveness in suppressing RCC growth. We
may also try to combine IL-2C with the current target
agents such as sorafenib to obtain additive effects.
Conclusions
Stimulating IL-2C treatment potentiated anti-tumor im-
munity without causing significant side effects; however,
given that the immune-enhancing effects of IL-2C were
not sufficiently strong to suppress RCC growth, its use
in combination with other therapy should be considered.
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